CORRESPONDENCE

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib

© The Author(s) 2022

Dear Editor,

Inferior outcomes have been observed with SARS-CoV-2 infection in patients with chronic myeloid neoplasms, emphasising the importance of development of robust immunity in this population. We and others have previously shown that a single dose of vaccine induces an immunological response in most patients with chronic myeloid malignancies [1–4]. However, the relatively small size of our initial cohorts limited analysis of certain subgroups, while other publications did not study the T cell response to vaccination, an essential component of vaccine efficacy [5]. We report here the humoral and T cell responses induced by sequential doses of vaccination against SARS-CoV-2 in patients with chronic myeloproliferative neoplasms as well as the early protective effect on infection in these patients.

Antibody testing was performed using ELISA for anti-S and anti-N IgG as well as neutralising antibody analysis as described previously [2]. T cell analysis was performed using the Fluorospot assay (Mabtech, Stockholm) with analysis on the IRIS reader using RAWspot technology, as described (Supplementary Methods, Supplementary Fig. 1a, b). Testing was performed in 61 patients including 24 with chronic myeloid leukaemia (CML), 11 with essential thrombocythaemia (ET), 13 with polycythaemia vera (PV) and 13 with myelofibrosis (MF) (Supplementary Tables 1 and 2). Patient samples were obtained at a median of 6.4 (IQR 4.9–8.4) weeks from a second dose of vaccine and 16.6 (14.7–18.5) weeks from the first dose. BNT162b2 vaccine (Pfizer, BioNTech) was used in 85.2% patients (52/61) while the remaining patients (14.8%, n = 9/61) received the ChAdOx-1-S vaccine (Astrazeneca).

At the time of submission 1/55 (1.8%) patients completing a post-vaccination survey had confirmed Covid-19 infection 4.5 months after receiving a second dose. This patient was taking ruxolitinib (20 mg, BD) and received the ChAdOx-1 vaccine, requiring hospitalisation with oxygen support for 12 days.

Serological analysis was performed in 60 patients following two doses of vaccine. Three patients had evidence of prior infection with elevated anti-Nucleocapsid IgG. Those with previous infection had higher anti-S IgG and neutralising antibody levels following vaccination than those without previous infection (EC50 5715 vs 1350, ID50 2035 vs 622, p = 0.0002/0.001, Supplementary Fig. 2a, b). There was strong correlation between total anti-S IgG and neutralising antibody levels with r = 0.74 (p < 0.001, Supplementary Fig. 3).

An Anti-S IgG response after two doses of vaccine was observed in 91.7% (55/60) of patients, increasing from 81.1% observed in 37 patients after a single dose (p = 0.2) (Supplementary Fig. 2c). A response rate of 96% (22/23) was observed in CML patients and 89.2% (33/37) in MPN patients. Patients with prior infection were excluded from subsequent anti-S IgG analyses. In CML patients the mean EC50 after a first dose was 275 compared to 1180 after a second dose (p = 0.056) (Supplementary Fig. 2e). Patients receiving the BNT162b2 vaccine had significantly higher anti-S IgG EC50 and neutralising antibody ID50 at 1420 and 691 compared with 154 and 198 in those receiving ChAdOx-1 (p = 0.05/0.04, Supplementary Fig. 4a, b). In addition, a negative or borderline anti-S IgG response at the limit of detection was observed in only 12.2% (6/49) of those receiving the BNT162b2 vaccine compared with 50% (4/8) of those receiving ChAdOx-1 (p = 0.025, Supplementary Fig. 4c).

Patients without seroconversion after 2 doses included three patients taking ruxolitinib, one on hydroxyurea and one on nilotinib. Five (8.3%) patients had borderline positive results including two patients taking ruxolitinib and three with CML on TKI therapy (imatinib n = 1, nilotinib n = 1, ponatinib n = 1). 50% of patients taking ruxolitinib had a negative or borderline response, significantly higher than that observed in patients not taking ruxolitinib and MPN patients not taking ruxolitinib (5/10 vs 5/47, 5/10 vs 1/25, p = 0.01/p = 0.004, Fig. 1a, b). Mean ruxolitinib dose was higher at 34 mg/day in those with negative or borderline response compared to 23 mg/day in those with a positive response (p = 0.14).

On multivariate analysis (MVA) (Supplementary Methods) for anti-S IgG response there was significant association with ruxolitinib treatment (MV OR = 0.04, 95% CI: 0.00–0.6, p = 0.04, Fig. 2) independently of potential confounders including age, sex, treatment, comorbidities, diagnosis and vaccine type. We also observed a significant association between presence of comorbidities and inferior anti-S IgG response to vaccination (MV OR = 0.05, 95% CI: 0.0–0.49, p = 0.02, Fig. 2). Vaccine type also showed a trend towards significance with superior anti-S IgG response observed in those receiving BNT162b2 (MV OR = 6.95 CI: 0.85–48.57, p = 0.07, Fig. 2).

T-cell analysis was performed in 60 patients after two doses. An overall T-cell response was observed in 88.3% (53/60) patients with an IFNγ response observed in 80% (48/60) and an IL-2 response in 68.3% (41/60). In total, participants had a mean of 74 spot forming units (SFU) for IFNγ and 26 for IL-2 secretion (p = 0.037, Supplementary Fig. 5a).

Non-responders included 2 patients taking ruxolitinib, 2 on ponatinib, 1 on hydroxyurea and 2 undergoing active surveillance. A polyfunctional T-cell response with secretion of IFNγ and IL-2 from the same SFU was observed in 63.3% (38/60) of patients. Excluding previous infection patients receiving ChAd-Ox-1 had lower mean SFUs for IFNγ and IL-2 at 9.7 and 3.1 respectively compared with 86.7 and 26.2 in those receiving BNT162b2, although not significant (p = 0.2/p = 0.2, Supplementary Fig. 4d, e).

Received: 28 January 2022 Revised: 16 March 2022 Accepted: 17 March 2022
Published online: 22 April 2022
Average relative spot volume (RSV) was calculated indicating the amount of cytokine secreted by each cell. Mean RSV of IFNγ was higher in reactive polyfunctional T cells at 8665 compared with 5204 within monofunctional cells ($p = 0.001$, Supplementary Fig. 5b).

Patients with previous infection were excluded from further analysis of T cell response. Patients with a diagnosis of ET had higher mean SFUs for IFNγ compared with other diagnoses with mean of 192.5 in ET, compared with 57.8 in CML, 65.4 in PV and 8 in MF ($p = 0.075$, $p = 0.03$ and $p = 0.058$ respectively, Supplementary Fig. 6a). Similarly mean SFUs for IL-2 was 66.3 for ET compared with 18.3 for CML, 17.5 for PV and 8.7 in MF ($p = 0.02$, $p = 0.03$ and $p = 0.01$ respectively, Supplementary Fig. 6b). Patients with ET had the highest frequency of polyfunctional SFUs with a mean of 14.8 compared with 4.3 in PV patients, 2.9 in CML patients and 0.9 in MF patients ($p = 0.13$, $p = 0.018$, and $p = 0.037$ respectively, Supplementary Fig. 6c).

Patients on ruxolitinib had mean SFUs of 7 for IFNγ compared with 119 for MPN patients not taking ruxolitinib ($p = 0.14$, Fig. 1c). Similarly mean SFU for IL-2 was 6.7 for ruxolitinib compared with 39.5 in MPN patients on other treatments or active surveillance ($p = 0.076$, Fig. 1d). Mean polyfunctional SFU was also reduced in those on ruxolitinib compared to other patients with MPN ($p = 0.11$, Fig. 1e). Amongst MPN patients on treatment, RSV of IFNγ was lowest in patients on ruxolitinib with a mean average RSV of 2942 compared with 7990 in patients on HC and 6687 in those on pegylated IFNa ($p = 0.016$ and $p = 0.0008$ respectively, Supplementary Fig. 7).

We have previously demonstrated that a single dose of BNT162b2 vaccine elicits both a humoral and cellular response in most patients...
with chronic myeloid neoplasms [1, 2]. Here we report that a second dose further increases the proportion of patients developing anti-S IgG antibodies and reactive T cells, as well as increasing the anti-S IgG EC50 observed in this patient group. We also demonstrate that patients with previous natural infection have significantly higher anti-S IgG and neutralising antibody levels following 2 doses of vaccine and observed an impaired response in those receiving ChAdOx-1 despite small numbers in this group.

MPN patients are recognised as often having immune deficiency which is heterogeneous and typically associated with a pro-inflammatory state that is influenced by the underlying diagnosis and different treatments. Patients taking ruxolitinib had significantly greater likelihood of having an undetectable or borderline antibody result. In addition, of those taking cytoreductive therapy, patients on pegylated IFNa and HC had significantly greater T-cell RSV for IFNg than patients taking ruxolitinib. We have previously shown that JAK inhibition reduces CD4+ T cell cytokine secretion, which may partially explain the findings observed [6]. In addition, ruxolitinib has been associated with a number of other detrimental effects on the immune system including reduced NK cell and dendritic cell function [7, 8]. Our findings are also supported by those observed in a recent study restricted to humoral responses following a single dose of mRNA vaccine in 18 patients taking ruxolitinib, although conflicting findings have also been reported [9, 10].

CML patients are also recognised to have leukaemia related immune deficiency which is most marked at diagnosis and typically improves with successful TKI therapy [11]. We have previously reported that CML patients, particularly those taking the dual ABL1/SRC kinase inhibitors dasatinib and bosutinib also have potential for significant T-cell dysfunction due to the pivotal role that these kinases play in signalling downstream from the T cell receptor [12]. We found greater IFNg T cell secretion in patients taking nilotinib, which is in keeping with our findings in CD4+ cells after a single vaccine dose [2].

Further studies are required to investigate the degree of antibody and T-cell responses required to provide adequate immunity in these patient groups, as well as longitudinal analysis to assess the dynamics of the response and impact of additional doses.

REFERENCES

1. Harrington P, de Lavallade H, Dooris KJ, O’Reilly A, Seow J, Graham C, et al. Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia. 2021;35:3573–7.

2. Harrington P, Dooris KJ, Rada D, O’Reilly A, Lam HPJ, Seow J, et al. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. Br J Haematol. 2021;194:999–1006.

3. Chowdhury O, Bruguier H, Mallett G, Sousos N, Crozier K, Allman C, et al. Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms. Br J Haematol. 2021;194:1010–5.

4. Maneekis K, Sablauskas K, Ringleviciute U, Vaitekenaitė V, Cekauskiene R, Kry-zauskaitė L, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8:e583–92.

5. Harrington P, Dooris KJ, Saha C, Saunders J, Child F, Dillon R, et al. Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T-cell response in allogeneic stem cell transplantation recipients. Cancer Cell. 2021;39:1448–9.

6. Keohane C, Kardasti S, Seidi T, Perez Abellan P, Thomas NS, Harrison CN, et al. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol. 2015;171:60–73.

7. Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurs C, et al. The JAK inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122:1192–202.

8. Schonberg K, Rudolph J, Vannahme M, Parampalli Yajnanarayana S, Cornez I, Hejazi M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 2015;75:2187–99.

9. Guglielmelli P, Mazzoni A, Maggi L, Kirs S, Zammarchi L, Pilerci S, et al. Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasms patients receiving ruxolitinib. Am J Hematol. 2021;96:E408–E10.

10. Caocci G, Mulas O, Mantovani D, Costa A, Galizia A, Barabino L, et al. Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis. Ann Hematol. 2021;101:929–31.

11. Hughes A, Clarkson J, Tang C, Vidovic L, White DH, Hughes TP, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood. 2017;129:1166–76.

12. Harrington P, Dillon R, Radia DH, McLornan DP, Rousselot P, Rezvani K, et al. Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML. Blood. 2020;136:51–3.

ACKNOWLEDGEMENTS

Blood Cancer UK grant to PH and HdL; MPN Voice grant to PH, CH, HdL; King’s Together Rapid COVID-19 Call awards to MMH, KJD; A Huo Family Foundation Award to MMH, KJD; Chronic Disease Research Foundation award CDRF-22/2020 to KJD, MMH; Wellcome Trust Investigator Award 106223/Z/14/Z to MMH; Fondation Dormeur, Vaduz for funding equipment to KJD, Mabtech, Stockholm for providing equipment to PH.

AUTHOR CONTRIBUTIONS

PH designed and performed the research, analysed data and wrote the manuscript. KD, TL, HK and MM performed the research and reviewed the manuscript. JS, CS, HPL, AOR, CW, SA, RD, NCG, JOS, SK, KR DR DM and CH assisted with patient recruitment and reviewed the manuscript. HdL designed the research, analysed data and wrote the manuscript.

COMPETING INTERESTS

PH reports research funding from Bristol Myers Squibb and speaker’s fees from Incyte. DM has received speaker fees and advisory boards Novartis, Celgene and Jazz Pharmaceuticals. CH has received speaker fees from Novartis, Janssen, CTI, Celgene, Medscape and has served on the Advisory Board for Incyte, CTI, Sierra Oncology, Novartis, Celgene, Roche, AOP pharma, Geron and Astra Zenica. HdL has received research grants and honoraria from Incyte and honoraria from Novartis and Pfizer.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41408-022-00651-3.

Correspondence

The online version contains supplementary material available at https://doi.org/10.1038/s41408-022-00651-3.

Reprints and permission information Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
